CytomX Therapeutics, Inc.-Product Pipeline Review-2015

CytomX Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07185CDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

CytomX Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'CytomX Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the CytomX Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytomX Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of CytomX Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of CytomX Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the CytomX Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate CytomX Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of CytomX Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the CytomX Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of CytomX Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytomX Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of CytomX Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

CytomX Therapeutics, Inc. Snapshot 5

CytomX Therapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

CytomX Therapeutics, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

CytomX Therapeutics, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

CytomX Therapeutics, Inc.-Pipeline Products Glance 11

CytomX Therapeutics, Inc.-Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

CytomX Therapeutics, Inc.-Drug Profiles 13

CTX-023 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

CTX-033 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

CTX-1003 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Monoclonal Antibody Conjugates for Cancer 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Monoclonal Antibody Conjugates for Oncology 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Monoclonal Antibody to Inhibit PD-L1 For Cancer 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Monoclonal Antibodies for Cancer 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Monoclonal Antibodies for Oncology 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Monoclonal Antibodies to Target CTLA-4 for Cancer 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibody Conjugated for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibody to Target Notch Pathway for Cancer 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

CytomX Therapeutics, Inc.-Pipeline Analysis 26

CytomX Therapeutics, Inc.-Pipeline Products by Target 26

CytomX Therapeutics, Inc.-Pipeline Products by Molecule Type 27

CytomX Therapeutics, Inc.-Pipeline Products by Mechanism of Action 28

CytomX Therapeutics, Inc.-Recent Pipeline Updates 29

CytomX Therapeutics, Inc.-Dormant Projects 30

CytomX Therapeutics, Inc.-Locations And Subsidiaries 31

Head Office 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

CytomX Therapeutics, Inc., Key Information 5

CytomX Therapeutics, Inc., Key Facts 5

CytomX Therapeutics, Inc.-Pipeline by Indication, 2015 8

CytomX Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

CytomX Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

CytomX Therapeutics, Inc.-Preclinical, 2015 11

CytomX Therapeutics, Inc.-Discovery, 2015 12

CytomX Therapeutics, Inc.-Pipeline by Target, 2015 26

CytomX Therapeutics, Inc.-Pipeline by Molecule Type, 2015 27

CytomX Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 28

CytomX Therapeutics, Inc.-Recent Pipeline Updates, 2015 29

CytomX Therapeutics, Inc.-Dormant Developmental Projects,2015 30

List of Figures

CytomX Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 7

CytomX Therapeutics, Inc.-Pipeline by Stage of Development, 2015 9

CytomX Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 10

CytomX Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 26

CytomX Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 27

CytomX Therapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of CytomX Therapeutics, Inc.; CytomX Therapeutics, Inc. - Key Therapeutics; CytomX Therapeutics, Inc. - Pipeline Overview and Promising Molecules; CytomX Therapeutics, Inc. - News; CytomX Therapeutics, Inc. - Latest Updates; CytomX Therapeutics, Inc. - Pipeline; CytomX Therapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]